The World Health Organization’s approach to nicotine harm reduction has been a source of sustained frustration for public health researchers, tobacco control specialists, and harm reduction advocates who believe the evidence supports a more nuanced position than the agency consistently adopts. The WHO’s posture — which tends to treat all nicotine products as equivalently problematic regardless of their risk profile relative to combustible tobacco — has real consequences for how member states approach regulation and how the harm reduction case gets heard in international policy settings.
The organisation’s Framework Convention on Tobacco Control, adopted in 2003 and before e-cigarettes or modern nicotine pouches existed as meaningful product categories, has been stretched to cover these newer products in ways that prioritise caution over evidence. The FCTC’s Conference of Parties has repeatedly declined to adopt frameworks that would distinguish between combustible and non-combustible nicotine products by risk, instead applying precautionary logic that treats novelty and uncertainty as grounds for restriction regardless of the comparative risk picture.
This position has been criticised by researchers who point out that the WHO’s own data on smoking mortality — approximately 8 million deaths per year globally — represents the cost of the status quo that the agency’s restrictive approach to alternatives helps maintain. If alternative products provide a pathway away from combustible tobacco for current smokers, restricting those alternatives preserves the cigarette market. The logic, its critics argue, is self-defeating from a public health standpoint.
The WHO’s defenders would argue that the agency must take a conservative position in the face of industry influence, that the long-term effects of alternative products are genuinely uncertain, and that protecting young people from new pathways to nicotine dependence is a legitimate priority. These are reasonable arguments that deserve engagement. What they do not do is fully account for the evidence on relative risk or the opportunity cost of restricting alternatives that could help current smokers.
The organisation’s approach is not monolithic — individual departments and researchers within the WHO system hold more nuanced views. But the institutional voice on this question has been consistently restrictive, and that voice carries significant weight in the policy deliberations of member states that lack the domestic research capacity to develop their own evidence base.
